scholarly journals American Thyroid Association Sonographic Risk and Afirma Gene Expression Classifier Alone and in Combination for the Diagnosis of Thyroid Nodules with Bethesda Category III Cytology

Thyroid ◽  
2020 ◽  
Vol 30 (11) ◽  
pp. 1613-1619
Author(s):  
Marilyn Arosemena ◽  
Anu Thekkumkattil ◽  
Maria Linares Valderrama ◽  
Russ Kuker ◽  
Rosa Patricia Castillo ◽  
...  
Keyword(s):  
Gene Expression ◽  
Thyroid Nodules ◽  
American Thyroid Association ◽  
Gene Expression Classifier

scholarly journals Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel

2018 ◽  
Vol 126 (7) ◽  
pp. 471-480 ◽  
Author(s):  
Rachel C. Jug ◽  
Michael B. Datto ◽  
Xiaoyin “Sara” Jiang
Keyword(s):  
Gene Expression ◽  
Thyroid Nodules ◽  
Molecular Testing ◽  
Gene Expression Classifier

scholarly journals Shear wave elastography and Afirma™ gene expression classifier in thyroid nodules with indeterminate cytology: a comparison study

Endocrine ◽  
2018 ◽  
Vol 59 (3) ◽  
pp. 573-584 ◽  
Author(s):  
Ghobad Azizi ◽  
James M. Keller ◽  
Michelle L. Mayo ◽  
Kelé Piper ◽  
David Puett ◽  
...  
Keyword(s):  
Gene Expression ◽  
Shear Wave ◽  
Thyroid Nodules ◽  
Shear Wave Elastography ◽  
Comparison Study ◽  
Gene Expression Classifier ◽  
Indeterminate Cytology

UTILITY OF ULTRASOUND VERSUS GENE EXPRESSION CLASSIFIER IN THYROID NODULES WITH ATYPIA OF UNDETERMINED SIGNIFICANCE

2016 ◽  
Vol 22 (10) ◽  
pp. 1199-1203 ◽  
Author(s):  
Carmen V. Villabona ◽  
Vineeth Mohan ◽  
Karla M. Arce ◽  
Julia Diacovo ◽  
Alisha Aggarwal ◽  
...  
Keyword(s):  
Gene Expression ◽  
Thyroid Nodules ◽  
Versus Gene ◽  
Gene Expression Classifier ◽  
Undetermined Significance

scholarly journals The Impact of Benign Gene Expression Classifier Test Results on the Endocrinologist–Patient Decision to Operate on Patients with Thyroid Nodules with Indeterminate Fine-Needle Aspiration Cytopathology

Thyroid ◽  
2012 ◽  
Vol 22 (10) ◽  
pp. 996-1001 ◽  
Author(s):  
Daniel S. Duick ◽  
Joshua P. Klopper ◽  
James C. Diggans ◽  
Lyssa Friedman ◽  
Giulia C. Kennedy ◽  
...  
Keyword(s):  
Gene Expression ◽  
Fine Needle Aspiration ◽  
Thyroid Nodules ◽  
Needle Aspiration ◽  
Test Results ◽  
Fine Needle ◽  
Patient Decision ◽  
Gene Expression Classifier ◽  
The Impact

scholarly journals Effect of Gene Expression Classifier Molecular Testing on the Surgical Decision-Making Process for Patients With Thyroid Nodules

2015 ◽  
Vol 141 (12) ◽  
pp. 1082 ◽  
Author(s):  
Salem I. Noureldine ◽  
Matthew T. Olson ◽  
Nishant Agrawal ◽  
Jason D. Prescott ◽  
Martha A. Zeiger ◽  
...  
Keyword(s):  
Gene Expression ◽  
Decision Making ◽  
Thyroid Nodules ◽  
Decision Making Process ◽  
Molecular Testing ◽  
Surgical Decision ◽  
Gene Expression Classifier ◽  
Surgical Decision Making

scholarly journals Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes

2017 ◽  
Vol 125 (5) ◽  
pp. 313-322 ◽  
Author(s):  
Sylvan C. Baca ◽  
Kristine S. Wong ◽  
Kyle C. Strickland ◽  
Howard T. Heller ◽  
Matthew I. Kim ◽  
...  
Keyword(s):  
Gene Expression ◽  
Clinical Outcomes ◽  
Thyroid Nodules ◽  
Cytologic Diagnosis ◽  
Gene Expression Classifier

Impact of the Afirma Gene Expression Classifier Result on the Surgical Management of Thyroid Nodules with Category III/IV Cytology and Its Correlation with Surgical Outcome

2016 ◽  
Vol 60 (3) ◽  
pp. 205-210 ◽  
Author(s):  
Shweta Chaudhary ◽  
Yanjun Hou ◽  
Rulong Shen ◽  
Shveta Hooda ◽  
Zaibo Li
Keyword(s):  
Gene Expression ◽  
Predictive Value ◽  
Surgical Outcome ◽  
Thyroid Nodules ◽  
Needle Aspiration ◽  
Follicular Neoplasm ◽  
Molecular Test ◽  
Gene Expression Classifier ◽  
Sensitivity Specificity ◽  
Undetermined Significance

Objective: The Afirma gene expression classifier (GEC) is a molecular test to further classify indeterminate fine-needle aspiration (FNA) as benign or suspicious for malignancy. Study Design: A total of 158 FNAs with Bethesda category III/IV cytology were sent for an Afirma GEC test. We correlated the Afirma GEC results with surgical outcome and also compared the data after Afirma's implementation with the data before. Results: Among the 158 FNAs, the Afirma result was benign in 63 (40%), suspicious in 85 (54%) and unsatisfactory in 10 (6%). In total, 73 (86%) suspicious Afirma cases had surgery and 28 (38%) showed carcinoma. In contrast, only 8 (13%) benign Afirma cases had surgery and all of them were benign. The sensitivity, specificity, negative predictive value and positive predictive value (PPV) of Afirma were 100, 15, 100 and 38%, respectively. The PPV was 20% in cases with follicular lesion of undetermined significance, but was 50% in cases suspicious for follicular neoplasm (SFN). The surgical excisional rate was significantly decreased in SFN cases after the Afirma test. Conclusions: The Afirma GEC is useful for further risk stratifying SFN cases.

Sign in / Sign up

Export Citation Format

Share Document